報道指內地中成藥集中採購浪潮將至 關注衝擊雙跨品種零售渠道
據《第一財經》報道,內地帶量採購將從化藥、高值耗材延伸至中成藥領域。在近期關於「中藥及配方顆粒進入集中採購」的話題討論中,內地醫保局明確回復,下一步,國家醫保局將會同有關部門在完善中成藥及配方顆粒質量評價標準的基礎上,從價高量大的品種入手,科學穩妥推進中成藥及配方顆粒集中採購改革。
有內地醫藥流通行業相關人士表示,因為中藥材的價格波動較大,會直接影響中成藥的價格,所以中成藥集採不會降價50%以上。
國內知名中藥營銷專家孫躍武認為,集採以後,中成藥市場規模將進一步縮小,企業的經營也會受到一定影響。目前,在醫院,西藥與中藥的銷售比例約為4:1,中藥規模比較小。此外,集採會對零售終端帶來影響,由於不少中藥產品屬於雙跨品種(指同一種藥品既是非處方藥又是處方藥),醫院集採導致產品價格下降後,會對藥店渠道的產品價格帶來直接衝擊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.